Parametric Portfolio Associates’s Arbutus Biopharma ABUS Stock Holding History

Parametric Portfolio Associates’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$509K	Buy	170,798 +157,240	+1,160%	+$481K	﹤0.01%	3090
2021 Q4	$53K	Buy	+13,558	New	+$52.7K	﹤0.01%	3593
2018 Q4	–	Sell	-105,617	Closed	-$998K	–	3900
2018 Q3	$998K	Buy	+105,617	New	+$1.05M	﹤0.01%	3098
2014 Q2	–	Sell	-35,569	Closed	-$764K	–	3722
2014 Q1	$764K	Buy	+35,569	New	+$639K	﹤0.01%	2888

Other funds holding ABUS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $77B AUM 10.33% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Parametric Portfolio Associates's ABUS Position: Q1 2022 in Review

Parametric Portfolio Associates increased its Arbutus Biopharma (ABUS) stake by 1,160% in Q1 2022, buying an estimated $481K and bringing the position to 170,798 shares worth $509K. The position accounts for ﹤0.01% of the portfolio, ranked #3090.

Parametric Portfolio Associates first reported a position in ABUS in Q1 2014 and has held it in 4 quarters since. The position peaked at $998K in Q3 2018. 119 funds tracked by Wall St. Rank hold ABUS as of Q1 2022.

Parametric Portfolio Associates held 170,798 shares of Arbutus Biopharma worth $509K as of Q1 2022.
Parametric Portfolio Associates bought 157,240 Arbutus Biopharma shares in Q1 2022, an estimated $481K.
Arbutus Biopharma made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3090 holding.
Parametric Portfolio Associates first reported a position in Arbutus Biopharma in Q1 2014 and has held it in 4 quarters since.
Parametric Portfolio Associates's Arbutus Biopharma position peaked at $998K in Q3 2018.
119 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.